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success of iliac angioplasty has been shown to
depend on indication, lesion severity, runoff, sex,
and lesion location.2-6 External iliac lesions general-
ly have a patency inferior to that seen in common
iliac lesions.2,6,7 Although the treatment of isolated
iliac stenoses with endovascular techniques has
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Background: Patients who require angioplasty and stenting of multiple iliac arterial seg-
ments often require reintervention to maintain long-term patency. Morphologic predic-
tors and causes of failure are unknown. The purpose of the current study was to define
arteriographic predictors of angioplasty and selective stent failure in the treatment of
multisegment iliac occlusive disease.
Methods: All iliac segments (two common and two external) of 75 patients who under-
went angioplasty and selective stent placement for multisegment iliac occlusive disease 
(≥ two segments) were scored through use of a modification of the Society of
Cardiovascular and Interventional Radiology classification for iliac angioplasty (0 = no
lesion; 4 = most severe). Total iliac score was calculated by summing scores from each
segment. A separate external iliac score was calculated by adding only the external iliac
scores. Arteriograms were reviewed initially and at the time of lesion recurrence and
stratified by lesion location and previous intervention.
Results: The area of previous endovascular intervention was the site of recurrence in 75%
of patients. New lesions, presumably a result of progressive atherosclerosis, occurred in
15% of patients, and lesions occurred in both new and previously treated iliac segments in
10% of patients. Only the external iliac score was an independent predictor of failed
endovascular therapy despite reintervention. For patients with an external iliac score of 2
or less, the endovascular primary-assisted patency rates at 6, 12, and 24 months were 96%,
92%, and 89%, respectively. This was improved in comparison with the 90%, 63%, and 45%
patency rates observed in patients with an external iliac score of 3 or more (P = .001).
Patients with an external iliac score of 3 or more had a significantly lower incidence of
hemodynamic and clinical improvement after intervention and a threefold higher need for
surgical inflow procedures than patients with an external iliac score of 2 or less.
Conclusions: Lesion formation after treatment of multisegment iliac occlusive disease
typically occurs in areas of prior intervention. The extent of external iliac disease can be
used to stratify patients with multisegment iliac occlusive disease who will likely respond
to endovascular treatment with a durable result. Patients with extensive external iliac
disease (score ≥ 3) have poor results after angioplasty and selective stenting as applied in
this study, even with endovascular reintervention. They are ideal subjects for prospective
comparative studies of competing initial therapies, including stenting, endografting, and
aortobifemoral bypass grafting. (J Vasc Surg 2000;32:564-9.)
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Iliac artery angioplasty and selective stent place-
ment for isolated iliac artery stenosis have become
the preferred treatments for localized aortoiliac
occlusive disease. The 4-year success rate for iliac
angioplasty is approximately 44% to 65% and is
increased to 53% to 77% after stent placement.1 The
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become commonplace, the use of these techniques
in the treatment of patients with multisegment iliac
disease has not been thoroughly studied.
Laborde et al8 have examined the influence of
anatomic distribution of atherosclerosis on outcome
of iliac stent placement. They compared the iliac
patency in patients treated for focal iliac lesions with
that in patients with external iliac lesions and in
patients with multilevel disease. In their study,
patients with multilevel disease had a sustained clin-
ical benefit of 60%; this compared with 92% for
patients with common iliac lesions and 98% for
patients with external iliac lesions.8
An American Heart Association multidisciplinary
advisory committee has published recommendations
on the use of iliac angioplasty in the treatment of
aortoiliac occlusive disease.9 The committee recom-
mended that most patients with multiple tandem
stenoses or with diffuse iliac occlusive disease involv-
ing both common and external iliac arteries should
undergo surgical bypass grafting. However, the data
underlying these recommendations were reviewed
before many iliac stent studies had been completed.
Because recent reports suggest an improved iliac
patency with the use of stents, the role of endovas-
cular treatment in multisegment aortoiliac occlusive
disease may warrant reevaluation.
We have recently reported the outcome of
endovascular treatment of multisegment iliac occlu-
sive disease as well as risk factors that predict poor
outcome.10 The presence of an external iliac artery
lesion, the occurrence of a procedural complication,
and preintervention thrombolysis were independent
predictors of failed primary patency. Of these, the
presence of an external iliac lesion was most predic-
tive of failed primary and primary-assisted patency.
Patients with an external iliac lesion had an iliac
patency of only 18% at 36 months after endovascu-
lar intervention. However, this poor primary iliac
patency could be improved to 58% with reinterven-
tion. Almost half of the patients in this series
required reintervention to maintain iliac patency.
The question left unanswered by this study was
whether there was a subgroup of patients with exter-
nal iliac disease who were likely to fail endovascular
therapy even with reintervention and who might be
better served by aortobifemoral bypass grafting as
their initial procedure. In the current study, we
reviewed the preintervention arteriograms in detail
for these patients to examine the morphologic char-
acteristics of their iliac occlusive disease. In particu-
lar, lesion length, location, and stenosis severity were
measured to identify a subgroup of patients with
external iliac disease in whom endovascular therapy
was unlikely to provide adequate patency. In addi-
tion, we examined the site of recurrent iliac disease
after initial endovascular intervention.
The mechanism by which endovascular treat-
ment fails is unknown. It is unclear whether inter-
vention fails because of lesion recurrence at the
treated site or because of disease progression in pre-
viously untreated areas. Thus, the purpose of this
study was to determine lesion-specific variables that
predict the outcome of endovascular therapy in
patients with multisegment iliac occlusive disease
involving either bilateral common iliac arteries or a
combination of common and external iliac artery
segments. In addition, we identified the sites of
lesion recurrence, which may provide insight into
the mechanisms by which endovascular therapy fails.
METHODS
Between July 1992 and December 1998, the
arteriograms of 75 patients who underwent angio-
plasty or stenting of at least two separate iliac artery
segments were identified by chart review and billing
records. This could include bilateral common iliac
lesions, bilateral external iliac lesions, or some com-
bination of common and external iliac lesions.
Demographic data, as well as patient specific vari-
ables that might have affected patency, have been
previously reported.10
Lesion-specific variables that might affect paten-
cy were measured through use of a modification of
the Society of Cardiovascular and Interventional
Radiology (SCVIR) classification system (Table I).11
Preintervention arteriograms were reviewed in a
blinded manner (without knowledge of outcome),
and the occlusive lesions involving the common and
external iliac arteries were scored. Lesion morpholo-
gy and dimensions were measured through use of
magnification and calipers. A stenosis was defined as
either a > 50% diameter reduction on arteriography
in comparison with a disease-free portion of the dis-
tal artery or a < 50% diameter reduction with an
unenhanced gradient of more than 10 mm Hg or an
Table I. Modified SCVIR guidelines for grading
iliac artery lesions11
Grade Morphologic description
0 No lesion
1 Symmetric lesion < 3 cm
2 Lesion 3-5 cm
3 Lesion > 5 cm
4 Occlusion
enhanced gradient of more than 20 mm Hg after
intra-arterial injection of 100 µg of nitroglycerin.
Most studies were performed through use of a digital
subtraction technique in which either a marker
catheter or the markers on the angioplasty balloon
were used to standardize for length to measure each
individual lesion. The disease severity for all four iliac
arteries—the total iliac score—was determined by
summing the score for each of the four iliac segments.
The external iliac score and common iliac score were
similarly obtained by summing the scores of lesions
located within the respective segments. Arteriograms
of patients with recurrent disease were also reviewed
for location and extent of lesion recurrence.
The effect of disease severity in the various iliac
segments on intervention patency was then deter-
mined through use of a Cox proportional hazard
analysis. In addition, patient-specific variables that
have previously been shown to affect patency were
included in this model to determine which of all of
the variables is most useful in predicting failed
patency.
Specific lesions were treated either with angio-
plasty and selective stenting or with primary stent-
ing. Specific lesions were treated with angioplasty,
and stent placement was performed for a technically
poor result or a residual pressure gradient of more
than 10 mm Hg. Primary stents were placed for
chronic iliac occlusions. Both balloon-expandable
stents (Palmaz, Cordis, Miami Lakes, Fla) and self-
expanding stents (Wallstent, Schneider, Inc, Min-
neapolis, Minn; Symphony Nitinol Stent, Boston
Scientific, Boston, Mass; Memotherm, Bard, Murray
Hill, NJ) were used. Patients were maintained on
aspirin after the procedure. Other anticoagulants
were not used unless indicated for other associated
conditions, such as atrial fibrillation.
Technical success was defined as an unenhanced
pressure gradient less than 10 mm Hg across the
treated iliac system after intervention. Assessment of
hemodynamic success was evaluated (as described in
the SVS/ISCVS reporting standards) as an increase
in the corresponding lower extremity ankle brachial
index (ABI) of at least 0.1.12 Clinical success was
determined through use of the American Heart
Association classification.9
Assessment of aortoiliac patency was determined
through use of the SVS/ISCVS criteria. Because
most patients underwent bilateral iliac intervention,
patency determination included analysis of both iliac
arteries and was not analyzed on a unilateral iliac
artery basis. Thus, in this study, iliac patency refers to
bilateral iliac arteries unless otherwise specified.
Patients were followed up through the use of 
physical examinations and segmental Doppler scan
pressure recordings. Patients who remained asympto-
matic with a normal femoral pulse and normal seg-
mental pressures were determined to have a patent
intervention. Patients with recurrent symptoms and a
decreased femoral pulse or a decrease in ABI of more
than 0.15 underwent either iliac artery duplex scan-
ning or arteriography to identify restenosis. A 
stenosis > 50% diameter reduction, an unenhanced
gradient more than 10 mm Hg, or a localized duplex
scanning peak systolic velocity increase more than
2.5× was considered evidence of recurrent disease.
Endovascular primary patency was defined as a patent
artery without recurrent stenosis or further endovas-
cular intervention. Primary-assisted patency was
defined as a patent artery that required repeat
endovascular intervention to treat recurrent stenosis.
Endovascular failure was defined as the development
of recurrent stenosis not amenable to endovascular
reintervention. The decision to undergo reinterven-
tion instead of surgical bypass grafting was made pri-
marily by the surgeon who was following up the
patient. Endovascular reintervention was attempted
unless the entire iliac system was occluded or very
diffuse recurrent disease was present.
Statistical analysis was performed through the
use of a microcomputer-based statistical program
(StatView, Abacus Concepts, Inc, Berkeley, Calif).
Patency rates were calculated through the use of the
Kaplan-Meier life table method, and the significance
between survival curves was determined through the
use of the log-rank test (Mantel-Cox). Cox propor-
tional hazards regression was performed in a 
stepwise fashion to identify variables that affected
patency. Logistic regression analysis was used to
determine which variables were associated with
hemodynamic failure, complications, and the need
for surgical bypass. Significance was assigned at a P
value less than .05. Numeric data are expressed as
means ± SEs.
RESULTS
During the study period, 75 patients had arterio-
grams before initial endovascular intervention.
Patients were 64% male, 30% diabetic, 68% active
smokers, and 60% claudicants. The mean age of the
patients was 64 ± 1 years. Twenty-eight patients
(38%) had recurrent lesions and underwent subse-
quent arteriograms for review.
The mean total iliac occlusive disease score for all
patients was 5.0 ± 0.3, the mean common iliac score
was 3.3 ± 0.1, and the mean external iliac score was
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1.7 ± 0.2. The cumulative endovascular failure rates
in patients with external iliac scores of 0, 1, and 2
were 12%, 10%, and 12%, respectively; these rates
progressively increased from 45% to 100% in patients
with scores from 3 to 6 (Fig 1). There were 22
patients (30%) with an external iliac score of 3 or
more; this score could result either from a unilateral
stenosis > 5 cm or from bilateral 3- to 5-cm stenoses.
There were eight patients with common or external
iliac occlusions.
Preintervention variables that were independent-
ly associated with reduced endovascular primary-
assisted patency included only the external iliac
artery score (Table II). The total and common iliac
scores were not predictive of failure. Of all the
patient-specific variables previously analyzed, only
the presence of a procedural complication was inde-
pendently associated with decreased endovascular
primary-assisted patency when external iliac score
was included in the regression analysis.
Outcomes for those patients with severe external
iliac disease (external iliac score ≥ 3) were generally
inferior to those for patients with less severe external
iliac disease (external iliac score ≤ 2). Patients with
an external iliac score of 3 or more had a significant-
ly lower incidence of hemodynamic and clinical
improvement after intervention and a threefold
higher need for surgical inflow procedures than
patients with an external iliac score of 2 or less
(Table III). In addition, the primary and primary-
Table III. Outcome of endovascular treatment of
multisegment iliac occlusive disease based on prein-
tervention external iliac score
External External 
iliac score iliac score 
≤ 2 ≥ 3 
Variable (n = 53) (n = 22) P value
Technical success (%) 98 91 .14
Hemodynamic success (%) 80 52 .02
Clinical success (%) 92 68 .007
Need for surgical inflow (%) 9 28 .05
Complication (%) 9 18 .28
Fig 1. Cumulative endovascular failure (%) based on preintervention external iliac score (P =
.01; χ2 test). n, Number of patients with score shown.
Table II. Cox proportional hazards model for pre-
dicting decreased iliac endovascular primary-assist-
ed patency
Relative 
Variable risk 95% CI P value
External iliac lesion 3.3 1.5-7.6 .0001
score (per increasing 
score)
Complication 3.3 1.1-10.2 .02
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assisted iliac patency rates for those patients with
severe external iliac disease (external iliac score ≥ 3)
were inferior to the rates for patients with less severe
external iliac disease (external iliac score ≤ 2; Figs 2
and 3). As early as 10 months after intervention,
endovascular primary iliac patency was significantly
better for patients with an external iliac score of 2 or
less than for patients with an external iliac score of 3
or more (P < .001; Fig 1). The endovascular prima-
ry-assisted patency rates for patients with an external
iliac score of 2 or less at 6, 12, and 24 months were
96%, 92%, and 89%, respectively. This was improved
in comparison with the 90%, 63%, and 45% patency
rates observed in patients with an external iliac score
of 3 or more (P = . 001; Fig 2).
Recurrent lesions developed in 38% of patients.
Of these, 75% recurred at the site of previously treat-
ed lesions, 15% occurred in previously untreated
areas, and 10% occurred in both new areas and pre-
viously treated regions. Patients with external iliac
lesions tended to have recurrences in previously
treated areas, whereas patients without external iliac
lesions tended to have lesions recur in new areas;
however, this difference did not reach statistical sig-
nificance (P = .1).
DISCUSSION
In our previous study, we found that patients
with multisegment iliac artery disease including an
external iliac lesion had a lower primary patency
after endovascular therapy.10 However, this differ-
ence was much less after reintervention. Lesion-
specific variables obtained from our current review
of pretreatment arteriograms identified subgroups
of patients who failed endovascular therapy, includ-
ing reintervention. Patients with a bilateral external
iliac score of 3 or more (which implies either a sin-
gle lesion > 5 cm or bilateral lesions 3-5 cm) had less
than 50% success after 2 years despite reintervention.
These are the patients who might benefit from ini-
tial surgical bypass grafting if they are appropriate
operative candidates.
In the current study, an analysis of independent
predictors of failed endovascular primary-assisted
patency showed that only increasing external iliac
disease severity, as measured by increasing external
iliac score, was predictive of failure. The disease
severity of the common iliac arteries was not predic-
tive. We found that an external iliac score of 3 or
more was the optimal threshold for predicting poor
outcomes. Patients with an external iliac score of 3
or more had only a 52% incidence of hemodynamic
improvement and a 68% incidence of clinical
improvement after intervention. In addition, these
Fig 3. Primary-assisted patency of aortoiliac segment for
patients with an external iliac score of 2 or less versus
patients with an external iliac score of 3 or more (P < .001
between groups; log-rank test). SE more than 0.1 at 13
months.
Fig 2. Primary patency of aortoiliac segment for patients
with an external iliac score of 2 or less versus patients with
an external iliac score of 3 or more (P < .0001 between
groups; log-rank test). SE more than 0.1 at 10 months.
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patients had markedly lower primary and secondary
patency rates than patients with less severe external
iliac disease. Although the iliac score of 3 or more
was an optimal prediction threshold, it is important
to keep in mind that the division of patients into
groups was arbitrary, because primary-assisted
patency failure increased continuously as the exter-
nal iliac score increased.
In our current study, patients without external
iliac artery lesions and those with single external iliac
lesions less than 5 cm or bilateral external iliac
lesions less than 3 to 5 cm (score ≤ 2) had a 3-year
primary patency rate of 54% and a primary-assisted
patency rate of 85% after reintervention. This prima-
ry-assisted patency obtained in patients with an
external iliac score of 2 or less compares favorably
with the 90% primary patency obtained at the same
time point with aortobifemoral bypass grafting.13
However, as previously reported, more than 40% of
patients required reintervention to achieve this 85%
primary-assisted patency. Whether this is a cost-
effective approach in the treatment of this cohort of
patients with multisegment iliac occlusive disease
remains to be evaluated.
The primary-assisted patency in patients with
severe external iliac artery disease, as measured by an
external iliac score of 3 or more, was only 45% at 24
months despite frequent reintervention. Patients
with multisegment iliac occlusive disease who have
severe external iliac disease have a poor outcome
after angioplasty and selective stenting despite rein-
tervention and may be considered for aorto-
bifemoral bypass grafting as their initial procedure.
Endovascular therapy in this cohort of patients
should be reserved for medically unfit individuals.
In the current study, there was no difference in
patency between lesions treated by angioplasty and
those treated by angioplasty followed by stent place-
ment. However, the selective stent strategy used in
this study would heavily bias the results toward
angioplasty alone, inasmuch as only patients with
suboptimal outcome after angioplasty received
stents.
In conclusion, we have found that most patients
who have recurrent disease after treatment of multi-
segment iliac occlusive disease do so in previously
treated lesions. Patients with multisegment disease
who do not have severe external iliac occlusive dis-
ease (bilateral score ≤ 2) have acceptable patency
after angioplasty and selective stent therapy but
require frequent reintervention. Patients with exten-
sive external iliac disease (single external iliac lesions
> 5 cm or bilateral external iliac lesions 3-5 cm; bilat-
eral score ≥ 3) have poor patency despite reinterven-
tion after angioplasty and selective stenting, as
applied in this study. Patients with multisegment
iliac occlusive disease who have extensive external
iliac involvement would be ideal candidates for a
randomized study to compare competing initial
therapies, including aortobifemoral bypass grafting,
angioplasty with stent placement, and stent grafting.
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